OneSource Specialty Pharma Ltd

OneSource Specialty Pharma Employee Stock Options

Onesource Specialty Pharma Limited has allotted 900 equity shares under its Employee Stock Option Plan. This allotment updates the company's total paid-up share capital.

OneSource Specialty Pharma Employee Stock Options

OneSource Specialty Pharma allotted 900 shares under its ESOP 2021 scheme at an exercise price of ₹278 per share, totaling ₹0.03 Crore.

Value

₹0.03 Cr

OneSource Specialty Pharma Management Change

Onesource Specialty Pharma Limited appointed B S R & Co LLP as its Statutory Auditor for a 60-month term, effective September 23, 2026.

OneSource Specialty Pharma Other Announcement

OneSource Specialty Pharma Ltd appointed M/s B S R & Co LLP as its Statutory Auditors for a five-year term ending at the 24th AGM.

OneSource Specialty Pharma Annual General Meeting

OneSource Specialty Pharma held its 19th Annual General Meeting on September 23, 2026. Shareholders transacted ordinary and special business items, including re-appointments and related party approvals.

OneSource Specialty Pharma Annual General Meeting

OneSource Specialty Pharma issued an addendum to its 19th AGM notice regarding additional disclosures for agenda items about material related party transactions.

OneSource Specialty Pharma Investor Presentation: Key Takeaways

OneSource reported strong Q1 FY27 results with Revenue of INR 4,490M (up 37% YoY) and EBITDA of INR 1,233M (up 39% YoY), driven by semaglutide commercialization and biologics expansion.

OneSource Specialty Pharma Earnings Call Transcript: Key Takeaways

Management is aggressively optimistic, leveraging the GLP-1 (Semaglutide) boom to mask temporary supply disruptions. Strategic shift toward CDMO for Softgel and Biologics aims to diversify beyond traditional captive manufacturing.

OneSource Specialty Pharma Q1 FY27 Results: Turns Profitable, Net Profit ₹25 Cr

OneSource Specialty Pharma Ltd reported revenue from operations of ₹449 Cr (+37.2% YoY) and net profit of ₹25 Cr for Q1 FY27.

Key figure

Net profit ₹25 Cr

OneSource Specialty Pharma Earnings Call: Key Takeaways

Q4 FY26 marked a strong recovery with 47% sequential revenue growth to US$48M, driven by Semaglutide launches and drug-device combinations.

OneSource Specialty Pharma Earnings Call: Key Takeaways

Onesource Q4 FY26 shows strong sequential recovery driven by semaglutide drug-device combination launches, although annual profits were dragged down by prior delays and exceptional items.

OneSource Specialty Pharma Q4 FY26 Results: Net Profit ₹4.6 Cr, Down 95.3% YoY

OneSource Specialty Pharma Ltd reported revenue from operations of ₹428.2 Cr (+0.5% YoY) and net profit of ₹4.6 Cr (-95.3% YoY) for Q4 FY26.

Key figure

Net profit ₹4.6 Cr · -95.3% YoY